title: 32P chromic phosphate radiosynovectomy for chronic haemophilic synovitis.
abstract: The principal medical consequence of haemophilia is the development of arthropathy, initiated by a haemarthrosis giving rise to chronic synovitis. Traditional methods of synovectomy include open excision and arthroscopy each of which require substantial amounts of clotting factor concentrate for several weeks, and in the case of open synovectomy, is often associated with loss of range of motion and arthrofibrosis. Radiosynovectomy, the intra-articular injection of low penetration radiocolloids, has been utilized outside the United States for over 20 years. Since 1988, our centre has performed 170 radiosynovectomies utilizing 32P chromic phosphate (32P). This study reports results of 130 32P radiosyovectomies with an average follow-up of 36.5 months (6-140 months). For primary procedures, excellent and good results (haemarthrosis reduction from 75 to 100%) were obtained in 79.2% of cases at 6 months to 8 years. For repeat procedures a combination of excellent and good results were obtained in 62.4% of cases at 6 months to 3 years. Regression analysis showed no correlation between results and age or degree of arthropathy. Radiation was well contained within the joint. There were no observed or identified complications. The procedure is highly cost effective in comparison to open surgical or arthroscopic synovectomy.
authors.affiliation: Los Angeles Orthopaedic Hospital, Los Angeles, CA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Silva
authors.forename: J V
authors.initials: JV
authors.lastname: Luck
authors.forename: M E
authors.initials: ME
authors.lastname: Siegel
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D017608:Chromium Compounds / Q000008:administration & dosage* / Q000627:therapeutic use; D002908:Chronic Disease; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006395:Hemarthrosis / Q000150:complications / Q000188:drug therapy / Q000209:etiology; D006467:Hemophilia A / Q000150:complications* / Q000473:pathology / Q000628:therapy; D006470:Hemorrhage; D006801:Humans; D007270:Injections, Intra-Articular; D008875:Middle Aged; D010710:Phosphates / Q000008:administration & dosage* / Q000627:therapeutic use; D010761:Phosphorus Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D012189:Retrospective Studies; D018570:Risk Assessment; D000074402:Synovectomy; D013585:Synovitis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D017608:Chromium Compounds; D010710:Phosphates; D010761:Phosphorus Radioisotopes; C509369:chromic phosphate